SCHEMBL2746872

SCHEMBL2746872

O=c1c(O)c(-c2ccc(-c3oc4ccccc4c(=O)c3O)cc2)oc2ccccc12

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.90
KMT2A Q03164 13/20 0.90
CYP3A4 P08684 12/20 0.90
HSD17B10 Q99714 10/20 0.90
MAPK1 P28482 7/20 0.90
HPGD P15428 7/20 0.90
ALDH1A1 P00352 6/20 0.90
ALOX15 P16050 5/20 0.90
USP2 O75604 3/20 0.90
SMN1; SMN2 Q16637 1/20 0.90
FTO Q9C0B1 1/20 0.90
KDM4E B2RXH2 14/20 0.90
TP53 P04637 9/20 0.90
LMNA P02545 4/20 0.90
CA12 O43570 1/20 0.90
CA1 P00915 1/20 0.90
CA2 P00918 1/20 0.90
ABCB1 P08183 1/20 0.90
CALM1 P0DP23 1/20 0.90
AR P10275 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL76636 0.95 KDM4E (0.93) MEN1KMT2ACYP3A4HSD17B10MAPK1
SCHEMBL345696 0.95 MEN1 (1.00) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL29433939 0.95 KDM4E (1.00) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL1679068 0.95 KDM4E (1.00) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL20246 0.95 KDM4E (1.00) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL31328341 0.93 KDM4E (0.97) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL31570209 0.93 KDM4E (0.97) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL21874433 0.93 KDM4E (0.97) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL21874432 0.93 KDM4E (0.97) MEN1KMT2ACYP3A4HSD17B10MAPK1
Flavonol SCHEMBL2386663 0.93 KDM4E (0.97) MEN1KMT2ACYP3A4HSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178702-B2 Composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2012-05-15 US claimed
US-20080265176-A1 COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2008-10-30 US claimed
US-8178702-B2 Composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2012-05-15 US disclosed
US-8178702-B2 Composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2012-05-15 US disclosed
US-8178702-B2 Composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2012-05-15 US disclosed
US-7635778-B2 For example, 3-ethylcarbonate-2-(4-(3-ethylcarbonate-4-oxo-4H-chromen-2-yl)phenyl)-4H-chromen-4-one; authentication markers for use in data storage media substrates SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-12-22 US disclosed
US-7635778-B2 For example, 3-ethylcarbonate-2-(4-(3-ethylcarbonate-4-oxo-4H-chromen-2-yl)phenyl)-4H-chromen-4-one; authentication markers for use in data storage media substrates SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-12-22 US disclosed
US-7635778-B2 For example, 3-ethylcarbonate-2-(4-(3-ethylcarbonate-4-oxo-4H-chromen-2-yl)phenyl)-4H-chromen-4-one; authentication markers for use in data storage media substrates SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-12-22 US disclosed
US-20080265176-A1 COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2008-10-30 US disclosed
US-20080265176-A1 COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2008-10-30 US disclosed
US-20080265176-A1 COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2008-10-30 US disclosed
US-20070032640-A1 Cytokine receptor LUDWIG INSTITUE FOR CANCER RESEARCH (AU) 2007-02-08 US disclosed
US-20070032640-A1 Cytokine receptor LUDWIG INSTITUE FOR CANCER RESEARCH (AU) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032640-A1 Cytokine receptor IL6ST, IL6, IL1RN MEN1 4554/4885KMT2A 4817/4885CYP3A4 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.